Q3 2025 EPS Estimates for Gilead Sciences, Inc. Raised by Zacks Research (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILDFree Report) – Zacks Research increased their Q3 2025 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on Monday, June 3rd. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will post earnings per share of $2.06 for the quarter, up from their previous forecast of $2.05. The consensus estimate for Gilead Sciences’ current full-year earnings is $3.75 per share. Zacks Research also issued estimates for Gilead Sciences’ Q4 2025 earnings at $1.86 EPS and FY2025 earnings at $7.17 EPS.

Gilead Sciences (NASDAQ:GILDGet Free Report) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. Gilead Sciences’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the company posted $1.37 earnings per share.

Several other brokerages also recently commented on GILD. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a research note on Wednesday, April 24th. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. Maxim Group reduced their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. UBS Group reduced their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $83.69.

Read Our Latest Analysis on Gilead Sciences

Gilead Sciences Trading Down 0.0 %

Shares of Gilead Sciences stock opened at $63.85 on Thursday. The firm has a market capitalization of $79.55 billion, a PE ratio of 177.36, a price-to-earnings-growth ratio of 1.28 and a beta of 0.20. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The company’s fifty day moving average price is $66.83 and its two-hundred day moving average price is $73.79. Gilead Sciences has a 52-week low of $62.07 and a 52-week high of $87.86.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.82%. Gilead Sciences’s payout ratio is 855.56%.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.16% of the stock is owned by company insiders.

Institutional Trading of Gilead Sciences

A number of large investors have recently bought and sold shares of the business. Cetera Advisors LLC boosted its position in Gilead Sciences by 167.2% during the 1st quarter. Cetera Advisors LLC now owns 82,786 shares of the biopharmaceutical company’s stock worth $6,064,000 after acquiring an additional 51,801 shares during the last quarter. Cetera Investment Advisers boosted its position in Gilead Sciences by 127.6% during the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock worth $15,668,000 after acquiring an additional 119,909 shares during the last quarter. Atria Investments Inc boosted its position in Gilead Sciences by 16.2% during the 1st quarter. Atria Investments Inc now owns 89,515 shares of the biopharmaceutical company’s stock worth $6,557,000 after acquiring an additional 12,507 shares during the last quarter. Swedbank AB acquired a new position in Gilead Sciences during the 1st quarter worth approximately $134,489,000. Finally, Virtu Financial LLC acquired a new position in Gilead Sciences during the 1st quarter worth approximately $4,633,000. 83.67% of the stock is owned by institutional investors.

About Gilead Sciences

(Get Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Read More

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.